Chloroquine was shown in 2004 to be active in vitro against SARS coronavirus but is of unproven efficacy and safety in patients infected with SARS-CoV-2. The drug’s potential benefits and risks for COVID-19 patients, without and with azithromycin, is discussed by Dr. David Juurlink, head of the Division of Clinical Pharmacology and Toxicology at Sunnybrook Health Sciences Centre in Toronto.
- Strategies for Managing Stress and Burnout in Your Employees - 19th February 2025
- New Tool Can Detect Fast-Spreading SARS-CoV-2 Variants Early - 19th February 2025
- Cancer immunotherapy treatment dramatically reduces sunspots - 19th February 2025